Does the media prefer MRNA or RYTM?

In the previous week, Moderna had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Moderna and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.89 beat Moderna's score of 0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or RYTM?

In the previous week, Roivant Sciences had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Roivant Sciences and 4 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.37 beat Rhythm Pharmaceuticals' score of 0.89 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INSM or RYTM?

In the previous week, Insmed had 10 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Insmed and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.89 beat Insmed's score of 0.85 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTX or RYTM?

In the previous week, BioNTech had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 4 mentions for Rhythm Pharmaceuticals. BioNTech's average media sentiment score of 1.03 beat Rhythm Pharmaceuticals' score of 0.89 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VTRS or RYTM?

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Rhythm Pharmaceuticals' score of 0.89 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rhythm Pharmaceuticals (RYTM) Competitors

$106.60 +0.51 (+0.48%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$109.57 +2.97 (+2.79%)

As of 07/17/2026 07:59 PM Eastern

Compare

RYTM vs. MRNA, ROIV, INSM, BNTX, and VTRS

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? MarketBeat compares Rhythm Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rhythm Pharmaceuticals include Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Rhythm Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Moderna. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.62	-$2.82B	-$8.15	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

75.3% of Moderna shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Moderna had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 12 mentions for Moderna and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.89 beat Moderna's score of 0.34 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Moderna presently has a consensus price target of $38.27, suggesting a potential downside of 38.10%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 29.72%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Rhythm Pharmaceuticals beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Rhythm Pharmaceuticals has a consensus target price of $138.29, suggesting a potential upside of 29.72%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Roivant Sciences had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Roivant Sciences and 4 mentions for Rhythm Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.37 beat Rhythm Pharmaceuticals' score of 0.89 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market.

Summary

Roivant Sciences and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	38.72	-$1.28B	-$5.75	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

In the previous week, Insmed had 10 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Insmed and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.89 beat Insmed's score of 0.85 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Insmed presently has a consensus price target of $211.05, suggesting a potential upside of 94.84%. Rhythm Pharmaceuticals has a consensus price target of $138.29, suggesting a potential upside of 29.72%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Insmed has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

Summary

Insmed beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

BioNTech presently has a consensus target price of $129.13, suggesting a potential upside of 41.15%. Rhythm Pharmaceuticals has a consensus target price of $138.29, suggesting a potential upside of 29.72%. Given BioNTech's higher probable upside, research analysts clearly believe BioNTech is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

BioNTech has a net margin of -44.39% compared to Rhythm Pharmaceuticals' net margin of -93.33%. BioNTech's return on equity of -5.30% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Rhythm Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.13	-$1.29B	-$5.88	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

In the previous week, BioNTech had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 5 mentions for BioNTech and 4 mentions for Rhythm Pharmaceuticals. BioNTech's average media sentiment score of 1.03 beat Rhythm Pharmaceuticals' score of 0.89 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Viatris currently has a consensus target price of $17.50, suggesting a potential upside of 1.21%. Rhythm Pharmaceuticals has a consensus target price of $138.29, suggesting a potential upside of 29.72%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.41	-$3.51B	-$0.26	N/A
Rhythm Pharmaceuticals	$189.76M	38.50	-$196.54M	-$3.13	N/A

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Rhythm Pharmaceuticals' score of 0.89 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.9% of Viatris shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Viatris has a net margin of -2.04% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Viatris' return on equity of 19.04% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Viatris has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Summary

Rhythm Pharmaceuticals beats Viatris on 9 of the 16 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.27B	$3.69B	$6.89B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	8.84%
P/E Ratio	-34.06	20.85	27.14	23.89
Price / Sales	38.50	304.43	524.02	90.49
Price / Cash	N/A	142.33	51.46	60.07
Price / Book	51.25	8.26	10.69	6.18
Net Income	-$196.54M	$23.83M	$3.59B	$331.73M
7 Day Performance	-1.66%	-3.48%	-2.18%	-2.04%
1 Month Performance	10.14%	2.58%	1.63%	-2.14%
1 Year Performance	19.51%	45.93%	25.56%	17.28%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	2.796 of 5 stars	$106.60 +0.5%	$138.29 +29.7%	+17.6%	$7.27B	$189.76M	N/A	140	News Coverage
MRNA Moderna	1.7736 of 5 stars	$67.01 -1.8%	$38.27 -42.9%	+92.0%	$27.09B	$1.94B	N/A	4,700	Gap Down
ROIV Roivant Sciences	1.7315 of 5 stars	$34.51 -4.1%	$33.59 -2.7%	+196.2%	$25.87B	$8.26M	N/A	860
INSM Insmed	4.092 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+4.0%	$25.06B	$606.42M	N/A	1,664	News Coverage Analyst Forecast Gap Down
BNTX BioNTech	4.5164 of 5 stars	$90.07 -1.6%	$129.13 +43.4%	-17.6%	$23.14B	$3.25B	N/A	7,807	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does Rhythm Pharmaceuticals compare to Moderna?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does Rhythm Pharmaceuticals compare to Moderna?

Which has more volatility and risk, MRNA or RYTM?

Which has preferable earnings & valuation, MRNA or RYTM?

Do insiders & institutionals hold more shares of MRNA or RYTM?

Does the media prefer MRNA or RYTM?

Is MRNA or RYTM more profitable?

Do analysts rate MRNA or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Do analysts rate ROIV or RYTM?

Does the media favor ROIV or RYTM?

Which has stronger valuation & earnings, ROIV or RYTM?

Is ROIV or RYTM more profitable?

Do insiders and institutionals hold more shares of ROIV or RYTM?

Which has more volatility & risk, ROIV or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Insmed?

Which has stronger earnings & valuation, INSM or RYTM?

Does the media favor INSM or RYTM?

Is INSM or RYTM more profitable?

Do analysts prefer INSM or RYTM?

Which has more risk & volatility, INSM or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Do analysts recommend BNTX or RYTM?

Is BNTX or RYTM more profitable?

Which has higher valuation and earnings, BNTX or RYTM?

Do institutionals and insiders hold more shares of BNTX or RYTM?

Which has more risk & volatility, BNTX or RYTM?

Does the media favor BNTX or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Viatris?

Do analysts recommend VTRS or RYTM?

Which has higher valuation and earnings, VTRS or RYTM?

Does the media prefer VTRS or RYTM?

Do institutionals & insiders have more ownership in VTRS or RYTM?

Is VTRS or RYTM more profitable?

Which has more volatility & risk, VTRS or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools